Bausch Health Companies Inc. · TSX:BHC
Bausch Health Companies — Shareholder Meeting (April 2021)
18 slides from Bausch Health Companies's shareholder meeting presentation, Apr 27, 2021
Slide 1: 2021 Annual Meeting of Shareholders
2021 Annual Meeting of Shareholders April 27, 2021
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking information and statements, within the meaning of expected timing of completion of such transaction and its terms, the Company’s ability to applicable securities laws (collectively, “forward-looking statements”), including, but no
Slide 3: Non-GAAP Information
Non-GAAP Information To supplement the financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP financial measures, including Adjusted EBITDA. Management uses non-GAAP measures as key metrics in the evaluation of company p
Slide 4: Introductions: Board of Directors
Introductions: Board of Directors Joseph C. Papa Thomas W. Ross, Sr. Richard U. DeSchutter D. Robert Hale Brett Icahn Argeris (Jerry) N. Chairman Lead Independent Director Karabelas Sarah B. Kavanagh Steven D. Miller John A. Paulson Robert N. Power Russel C. Robertson Andrew C. Amy B. von Eschenbach
Slide 5: Remarks from Chairman & CEO Joseph C. Papa
Remarks from Chairman & CEO Joseph C. Papa 2021 Annual Meeting of Shareholders April 27, 2021 4
Slide 6: Impact on the World Today
Impact on the World Today Every day more than 150 million people around the world use a Bausch Health product 5
Slide 7: Our Vision, Mission and Values
Our Vision, Mission and Values Our Vision: Core Values: To Be Your Trusted • Accountability Health Care Partner • Agility • Courage • Integrity • Teamwork • Results Orientation Our Mission: Improving People’s Lives With Our Health Care Products 6
Slide 8: Solid Momentum… …Well Positioned
Exited 2020 with …Well Positioned Solid Momentum… for 20211 Strong Execution Executing Our Business Recovery from COVID-19 • Outperformed high end of 2020 guidance by generating revenue for 2020 that exceeded • Positioned to benefit from tailwinds $8.0B from the recovery • Delivered strong adjusted
Slide 9: Strategic Focus
Strategic Focus Execution, Growth & Accelerating Strategic Alternatives Executing Our Business /International Recovery from COVID-19 Diversified Products Unleashing Growth Drivers Accelerating Strategic Actively pursuing all opportunities to Alternatives to Drive expedite leverage improvement and de
Slide 10: Unleashing Growth Drivers
Unleashing Growth Drivers Business Growth Drivers1 • SiHy daily: Ramp up and approvals globally • Cataract surgery tailwind: ▪ In U.S., ~4M surgeries are performed each year2 ▪ In 2020, we estimate ~650K surgeries or ~16% in U.S. were delayed while outside the U.S. we estimate 20% of the surgeries w
Slide 11: Near-term Catalysts
Near-term Catalysts1 R&D: Upcoming Milestones • Initiate Amiselimod S1P2 Modulator Phase 2 trial3 – 1H21 Phase 3 Topline Results • Readout of topline results of first of two Phase 3 trials for Statistically significant topline data from the first Phase 3 trial (GOBI trial) NOV03, an investigational
Slide 12: Accelerating Strategic Alternatives to Expedite Spin-off
Accelerating Strategic Alternatives to Expedite Spin-off1 • Financial segmentation of Bausch + Lomb anticipated to be complete Noteworthy by 1Q21 earnings (May) Milestones • All internal objectives necessary for the spin of Bausch + Lomb anticipated to be achieved by 3Q21 Potential Paths Forward: Us
Slide 13: Closing Remarks
Closing Remarks BAUSCH Health
Slide 14: 2021 Strategic Focus: Execution, Growth & Accelerating Strategic Alternatives
2021 Strategic Focus: Execution, Growth & Accelerating Strategic Alternatives Executing Our Unleashing Accelerating Business Growth Drivers Strategic Recovery from Alternatives to COVID-19 Drive Shareholder Value 13
Slide 15: Question & Answer Period
Question & Answer Period BAUSCH Health
Slide 16: Appendix
Appendix 15
Slide 17: Non-GAAP Appendix Adjusted EBITDA
Non-GAAP Appendix Adjusted EBITDA Adjusted EBITDA (non-GAAP) ongoing operations of the Company. As a result, the Company does not believe that such costs (and their impact) are truly representative of its Adjusted EBITDA (non-GAAP) is GAAP net income (loss) attributable to underlying business. The C
Slide 18: Non-GAAP Appendix Adjusted EBITDA
Non-GAAP Appendix Adjusted EBITDA Acquisition-related costs and adjustments excluding amortization of the sustainability of the Company's operating performance, allow for a intangible assets: The Company has excluded the impact of acquisition- comparison of the financial results to historical operat
Bausch Health Companies — Shareholder Meeting (April 2021) on 6ix